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Summary

Background Recent evidence indicates a potential therapeutic role of fluvoxamine for COVID-19. In the TOGETHER
trial for acutely symptomatic patients with COVID-19, we aimed to assess the efficacy of fluvoxamine versus placebo
in preventing hospitalisation defined as either retention in a COVID-19 emergency setting or transfer to a tertiary
hospital due to COVID-19.
Methods This placebo-controlled, randomised, adaptive platform trial done among high-risk symptomatic Brazilian
adults confirmed positive for SARS-CoV-2 included eligible patients from 11 clinical sites in Brazil with a known risk
factor for progression to severe disease. Patients were randomly assigned (1:1) to either fluvoxamine (100 mg twice
daily for 10 days) or placebo (or other treatment groups not reported here). The trial team, site staff, and patients were
masked to treatment allocation. Our primary outcome was a composite endpoint of hospitalisation defined as either
retention in a COVID-19 emergency setting or transfer to tertiary hospital due to COVID-19 up to 28 days postrandom assignment on the basis of intention to treat. Modified intention to treat explored patients receiving at least
24 h of treatment before a primary outcome event and per-protocol analysis explored patients with a high level
adherence (>80%). We used a Bayesian analytic framework to establish the effects along with probability of success of
intervention compared with placebo. The trial is registered at ClinicalTrials.gov (NCT04727424) and is ongoing.
Findings The study team screened 9803 potential participants for this trial. The trial was initiated on June 2, 2020,
with the current protocol reporting randomisation to fluvoxamine from Jan 20 to Aug 5, 2021, when the trial arms
were stopped for superiority. 741 patients were allocated to fluvoxamine and 756 to placebo. The average age of
participants was 50 years (range 18–102 years); 58% were female. The proportion of patients observed in a COVID-19
emergency setting for more than 6 h or transferred to a tertiary hospital due to COVID-19 was lower for the
fluvoxamine group compared with placebo (79 [11%] of 741 vs 119 [16%] of 756); relative risk [RR] 0·68; 95% Bayesian
credible interval [95% BCI]: 0·52–0·88), with a probability of superiority of 99·8% surpassing the prespecified
superiority threshold of 97·6% (risk difference 5·0%). Of the composite primary outcome events, 87% were
hospitalisations. Findings for the primary outcome were similar for the modified intention-to-treat analysis (RR 0·69,
95% BCI 0·53–0·90) and larger in the per-protocol analysis (RR 0·34, 95% BCI, 0·21–0·54). There were 17 deaths in
the fluvoxamine group and 25 deaths in the placebo group in the primary intention-to-treat analysis (odds ratio [OR]
0·68, 95% CI: 0·36–1·27). There was one death in the fluvoxamine group and 12 in the placebo group for the perprotocol population (OR 0·09; 95% CI 0·01–0·47). We found no significant differences in number of treatment
emergent adverse events among patients in the fluvoxamine and placebo groups.
Interpretation Treatment with fluvoxamine (100 mg twice daily for 10 days) among high-risk outpatients with early
diagnosed COVID-19 reduced the need for hospitalisation defined as retention in a COVID-19 emergency setting or
transfer to a tertiary hospital.
Funding FastGrants and The Rainwater Charitable Foundation.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND
4.0 license.

Introduction
Although safe and effective vaccines for COVID-19
have been developed and distributed, there remain,
particularly in low resource settings, major challenges
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regarding their production, allocation, and affordability.1
Identifying inexpensive, widely available, and effective
therapies against COVID-19 is, therefore, of great
importance. In particular, repurposing existing medicines
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Research in context
Evidence before this study
A search of PubMed on Sept 10, 2021 by means of the
following search terms “(randomized OR trial) AND
(fluvoxamine OR antidepressants OR selective serotonin
reuptake inhibitors OR SSRIs) AND (COVID* OR SARS-CoV-2 OR
SARS-CoV)”, with no date or language restrictions identified
one observational study that reported a significant association
between antidepressant use and reduced risk of intubation or
death (hazard ratio 0·56; 95% CI 0·43–0·73, p<0·001) and one
randomised clinical trial that reported that adult outpatients
with symptomatic COVID-19, treated with fluvoxamine,
compared with placebo, had a lower likelihood of clinical
deterioration over 15 days. In this preliminary randomised trial,
152 participants were randomly assigned to receive 100 mg of
fluvoxamine (n=80) or placebo (n=72) three times daily for
15 days; the primary endpoint was clinical deterioration within
15 days of randomisation defined by meeting criteria of

Added value of this study
TOGETHER is the largest randomised trial to assess the
effectiveness of fluvoxamine for patients with COVID-19 in the
community. Compared with placebo, patients randomly
assigned to fluvoxamine had a lower risk of hospitalisation
defined as either retention in a COVID-19 emergency setting or
transfer to a tertiary hospital due to COVID-19.
Implications of all the available evidence
There are few effective therapies for patients with COVID-19 in
the community. Results provide compelling evidence of
fluvoxamine’s benefit in reducing acute morbidity from
COVID-19 illness.

that are widely available and with well understood safety
profiles, has particular appeal.2
Fluvoxamine is a selective serotonin reuptake inhibitor
(SSRI) and a σ-1 receptor (S1R) agonist.3 There are several
potential mechanisms for fluvoxamine in treat
ment
of COVID-19 illness, including anti-inflammatory and
possible antiviral effects.4 A small placebo-controlled,
randomised trial has raised the possibility that
fluvoxamine might reduce the risk of clinical deterioration
in outpatients with COVID-19, suggesting the need for
larger randomised, placebo-controlled studies.5,6
To evaluate the efficacy of fluvoxamine to prevent
progression of COVID-19 and hospitalisation among
outpatients with laboratory-documented SARS-CoV-2, we
did a randomised, placebo-controlled, adaptive platform
trial in Minas Gerais, Brazil. This flexible platform trial
design allows for additional agents to be added and tested
with standardised operating procedures outlined in a
single overarching master protocol.7,8 Among eight
different interventions evaluated in this platform trial, we
report here on the clinical evaluation of fluvoxamine by
means of a concurrent placebo control group.

trial, thus far, include, hydroxychloroquine (protocol 1),
lopinavir–ritonavir (protocol 1),10 metformin, ivermectin,
fluvoxamine, doxasozin, and pegylated interferon lambda
versus matching placebos (protocol 2). The TOGETHER
trial is centrally coordinated by Platform Life Sciences
(Vancouver, Canada) with local implementation provided
by Cardresearch (Belo Horizonte, Brazil). Statistical
analyses were done by Cytel (Waltham, MA, USA).
The trial complies with the International Conference of
Harmonization—Good Clinical Practices as well as local
regulatory requirements. It was approved for research
ethics by local and national ethics boards in Brazil
(CONEP CAAE: 41174620.0.1001.5120, approval letter
5.501.284) and the Hamilton Integrated Research Ethics
Board (approval letter 13390) in Canada. The full protocol
and statistical analysis plan have previously been
published,9 and additional details are in appendix 2 (p 2).
The adaptive designs Consolidated Standards of
Reporting Trials extension statement guided this trial
report.10,11 An independent data safety monitoring
committee (DSMC) provided trial oversight.

Methods

The cities and investigators of the 11 clinical sites in
Brazil who participated in the trial are listed in
appendix 2 (p 3). Local investigators, in partnership with
local public health authorities, recruited participants at
community health facilities (emergency settings,
influenza-symptom referral centres, or primary care
community centres). We used several community
outreach strategies including physical and social media
as per local public health authorities, in order to create
awareness of the trial.
On presentation to one of the trial outpatient care
clinics, local investigators screened potential participants
to identify those who met the eligibility criteria. The

Study design
The TOGETHER trial is a randomised, adaptive platform
trial to investigate the efficacy of repurposed treatments
for COVID-19 disease among high-risk adult outpatients.9
The trial was designed and done in partnership with local
public health authorities from 11 participating cities
in Brazil to simultaneously test potential treatments
for early disease by means of a master protocol. A
master protocol defines prospective decision criteria for
discontinuing interventions for futility, stopping because
of superiority against placebo, or adding new inter
ventions. Interventions evaluated in the TOGETHER
e43

shortness of breath, hospitalisation for shortness of breath,
pneumonia and oxygen saturation less than 92%, or need for
supplemental oxygen to achieve oxygen saturation of 92%
or greater.

Participants

www.thelancet.com/lancetgh Vol 10 January 2022

Articles

key inclusion criteria were patients older than 18 years,
presenting to an outpatient care setting with an
acute clinical condition consistent with COVID-19 and
symptoms beginning within 7 days of the screening date,
or positive rapid test for SARS-CoV-2 antigen done at the
time of screening or patient with positive SARS-CoV-2
diagnostic test within 7 days of symptom onset. Eligible
patients also had at least one additional criterion for high
risk: diabetes; systemic arterial hypertension requiring at
least one oral medication for treatment; known
cardiovascular disease (heart failure, congenital heart
disease, valve disease, coronary artery disease,
cardiomyopathies being treated, clinically manifested
heart disease and with clinical repercussion); sympto
matic lung disease or treatment for such (emphysema,
fibrosing diseases); symptomatic asthma requiring
chronic use of agents to control symptoms; smoking;
obesity, defined as body-mass index greater than
30 kg/m² (weight and height information provided by
the patient); having had a transplant; stage IV chronic
kidney disease or on dialysis; immunosuppression or
use of corticosteroid therapy (equivalent to at least 10 mg
of prednisone per day) or immunosuppressive therapy;
history of cancer in the last 0·5 years or undergoing
current cancer treatment or aged 50 years or older; and
unvaccinated status.
Patients who met any of the following key criteria were
excluded from the trial: diagnostic examination for
SARS-CoV-2 negative associated with acute flu-like
symptoms (patients with negative test taken early and
becoming positive a few days later were eligible, if they
were less than 7 days after the onset of flu-like symptoms);
acute respiratory condition compatible with COVID-19
treated in primary care and previously requiring
hospitalisation; acute respiratory condition owing to
other causes; received vaccination for SARS-CoV-2;
dyspnoea secondary to other acute and chronic
respiratory causes or infections (eg, decompensated
chronic obstructive pulmonary disease, acute bronchitis,
pneumonia, primary pulmonary arterial hypertension);
current use of SSRIs (use of other serotonin reuptake
inhibitors were not excluded); uncontrolled psychiatric
disorders or suicidal ideation; inability or unwillingness
to follow research guidelines and procedures. A full list
of exclusion criteria is provided in the trial protocol.
If a patient met the aforementioned eligibility criteria,
study personnel obtained written informed consent. After
obtaining informed consent a rapid antigen test for
COVID-19 (Panbio, Abbott Laboratories Jena, Jena,
Germany) and a pregnancy test for women of childbearing
age were done. If the COVID-19 test was negative or if the
pregnancy test was positive, the participant was not
included in the trial. After informed consent, study
personnel collected the following data before randomi
sation: demographics, medical history, concomitant
medications, comorbidities, exposure to index case
information, WHO clinical worsening scale, and the
www.thelancet.com/lancetgh Vol 10 January 2022

patient-reported outcomes measurement information
(PROMIS) Global Health Scale.

Randomisation and masking
Participants were randomly assigned by means of a
centralised core randomisation process handled by an
independent unmasked pharmacist who was not aware of
any protocol-related procedures and contracted specifically
for this process. Sites requested randomisation by text
message to the pharmacist at the coordinating centre.
This maintained concealment of allocation. Patients were
randomly assigned (1:1) by means of a block randomisation
procedure for each participating site, stratified by age
(<50 years or ≥50 years). The trial team, site staff, and
patients were masked to treatment allocation. The active
drugs and the placebo pills were packaged in identically
shaped bottles and labelled with alphabet letters
corresponding to the active group or placebo group. Only
the third-party pharmacist responsible for releasing the
randomisation was aware of which letter was associated
with which drug or placebo. As this is a multiarm trial
and all active interventions have a matching inert placebo,
the matching placebo represents the proportion of the
control group for the number of arms in the trial at any
given time.

Procedures
All participants received usual standard care for
COVID-19 provided by health-care professionals at
public health facilities. Patients were randomly assigned
to fluvoxamine (Luvox, Abbott) at a dose of 100 mg twice
a day for 10 days or corresponding placebo starting
directly after randomisation (day 1). Research personnel
provided participants with a welcome video, which gave
information on the trial, study drug, adverse events, and
follow-up procedures. Clinicians providing usual care in
public health facilities typically focus on the management
of symptoms and provide antipyretics or recommend
antibiotics only if they suspect bacterial pneumonia.
Study personnel collected outcome data on days 1, 2, 3,
4, 5, 7, 10, 14, and 28 in person or via telephone contact or
social media applications using video-teleconferencing.
We collected outcome data irrespective of whether
participants took study medication. In case of adverse
events, unscheduled visits (during the treatment period)
outside of clinical care could occur at any time.
Considering the transmissible characteristics of SARSCoV-2 and the isolation recommendations of positive
individuals, we collected few vital sign data. Cardiac
safety was assessed by means of a six-lead electro
cardiogram (Kardiamobile, Mountain View, CA, USA) at
the baseline visit. The digital recordings were deidentified
and transferred to a central facility (Cardresearch, Belo
Horizonte, Brazil) for reading. Oxygen status was
assessed by means of a pulse oximeter for non-invasive
arterial oxygen saturation and pulse (Jumper Medical
Equipment, Shenzhen, China), and temperature by
e44
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9803 patients screened for eligibility

6480 excluded
6407 not eligible
73 withdrew consent

3323 randomly assigned

741 allocated to and received fluvoxamine

756 allocated to and received placebo

741 intention-to-treat population
740 modified intention-to-treat population—no
primary endpoint within 24 h of
randomisation
548 per-protocol >80% treatment adherence

756 intention-to-treat population
751 modified intention-to-treat population—no
primary endpoint within 24 h of
randomisation
619 per-protocol >80% treatment adherence

1826 allocated to other treatment groups

244 hydroxychloroquine

214 lopinavir–ritonavir

227 previous placebo

215 metformin

739 ivermectin

91 doxazosin

96 interferon-lambda

Figure 1: Trial profile

means of a standard digital oral thermometer
administered by research personnel. Mid-turbinate nasal
swab kits and sterile recipient storage were provided for
collection of nasopharyngeal swab or sputum–saliva.
Nasal swabs for PCR testing was completed on the first
quarter of participants enrolled in the trial on days 3 and
7. Viral clearance was assessed to establish whether active
drugs showed any antiviral effects.
All serious and non-serious adverse events were
reported to study personnel as per local regulatory
requirements. Reportable adverse events included
serious adverse events, adverse events resulting in study
medication discontinuation, and adverse events assessed
as possibly related to study medication.

Outcomes
Our primary outcome was a composite endpoint of
medical admission to a hospital setting due to COVID-19related illness defined as COVID-19 emergency setting
visits with participants remaining under observation for
more than 6 h or referral to further hospitalisation due to
the progression of COVID-19 within 28 days of
randomisation. Because many patients who would
ordinarily have been hospitalised were prevented from
e45

admission due to hospital over-capacity during peak
waves, the composite endpoint addresses both
hospitalisation and a proxy for hospitalisation, retention
in a COVID-19 emergency hospital setting. This region of
Brazil implemented hospital-like services in the
emergency settings with 50–80 bed units providing
services including multiday stays, oxygenation, and
mechanical ventilation. The 6 h threshold referred only to
periods of time recommended for observation by a
clinician and does not include waiting times. Key
secondary outcomes include viral clearance, time to
clinical improvement, number of days with respiratory
symptoms, time to hospitalisation for any cause or due to
COVID-19 progression, all-cause mortality and time to
death from any causes, WHO clinical worsening scale
score, days in hospital and on ventilator and adverse
events, adverse reactions to the study medications, and
the proportion of participants who are non-adherent with
the study drugs. All secondary outcomes were assessed
up to 28 days following randomisation.

Statistical analysis
The Adaptive Design Protocol and the Master Statistical
Analysis Plan provide details of sample size calculation
www.thelancet.com/lancetgh Vol 10 January 2022
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and statistical analysis.9 This trial is adaptive and applies
sample size reassessment approaches. To plan for each
arm, we assumed a minimum clinical utility of 37·5%
(relative risk reduction) to achieve 80% power with
0·05 two-sided type 1 error for a pairwise comparison
against the placebo assuming a control event rate
of 15%. This resulted in an initial plan to recruit
681 participants per arm. The statistical team did
planned interim analyses. Stopping thresholds for
futility were established if the posterior probability of
superiority was less than 40% at interim analysis. An
arm could be stopped for superiority if the posterior
probability of superiority met the threshold of 97·6%.
Baseline characteristics are reported as count (%) or
median and IQR for continuous variables. We applied a
Bayesian framework for our primary outcome analysis
and a frequentist approach for all sensitivity analyses
and secondary outcomes. Bayesian analysis allows us to
report the posterior probability of treatment efficacy at
the end of the trial, independently of the decisions
made along the way. Posterior efficacy of fluvoxamine
for the primary outcome is calculated by means of the
beta-binomial model for event rates, as detailed in the
appendix of the statistical analysis plan,12 assuming
informed priors on the basis of observational data for
both placebo and fluvoxamine, for both intentionto-treat and per-protocol analyses (defined as taking
>80% of possible doses). Modified intention to treat
(mITT) was defined as receiving treatment for at least
24 h before a primary outcome. We accounted for any
temporal changes in event rates by means of only
the concurrent randomised population. We assessed
subgroup effects according to the preplanned statistical
analysis plan. We calculated the number needed
to treat.
Secondary outcomes were assessed by means of a
prespecified frequentist approach. For viral clearance we
fitted a longitudinal, mixed-effect logistic regression
model with a treatment and time interaction term for
binary patient outcomes (COVID-19 positive–negative)
reported on day 3 and 7 from randomisation, with subject
random effect. We assessed time-to-event outcomes using
Cox proportional hazard models and binary outcomes
using logistic regression. Model assumptions were
evaluated by testing for proportionality. We did a subgroup
analysis and reported p values for the interactions. Perprotocol analyses were considered sensitivity analyses to
assess the robustness of the results. We followed the
statistical analysis plan and provided a post-hoc analysis
where requested by reviewers. All analyses were done by
means of R version 4.0.3. Full details of the statistical
analysis plan can be found in the Open Science Framework
under Data Section.
A data and safety monitoring committee provided
independent oversight for this trial. We planned a fourth
and final interim analysis of the fluvoxamine group
based on data up to Aug 2, 2021. Herein, we present
www.thelancet.com/lancetgh Vol 10 January 2022

Fluvoxamine
(n=741)

Placebo
(n=756)

Female

409 (55%)

453 (60%)

Male

332 (45%)

303 (40%)

Sex

Race
709 (96%)

719 (95%)

White

Mixed race*

6 (1%)

6 (1%)

Black or African American

5 (1%)

5 (1%)

21 (3%)

26 (3%)

<50

379 (51%)

368 (49%)

≥50

327 (44%)

328 (43%)

46 (6%)

49 (6%)

50 (39–56)

49 (38–56)

Unknown
Age, years

Unspecified
Age descriptive statistics
Median (IQR)
Body-mass index
<30 kg/m²

355 (48%)

373 (49%)

≥30 kg/m²

376 (51%)

375 (50%)

Unspecified

10 (1%)

8 (1%)

Time since onset of symptoms, days
0–3

328 (44%)

310 (41%)

4–7

239 (32%)

267 (35%)

Unspecified

174 (23%)

179 (24%)

Risk factors
Chronic cardiac disease
Uncontrolled hypertension
Chronic pulmonary disease
Asthma

9 (1%)

7 (1%)

106 (14%)

88 (12%)

6 (1%)
12 (2%)

3 (<1%)
16 (2%)

Chronic kidney disease

2 (<1%)

2 (<1%)

Rheumatological disorder

1 (<1%)

0

8 (1%)

6 (1%)

Type 1 diabetes

Chronic neurological disorder

25 (3%)

22 (3%)

Type 2 diabetes

104 (14%)

92 (12%)

Autoimmune disease
Any other risk factor(s) or comorbidities

0
25 (3%)

2 (<1%)
24 (3%)

Data are n (%). *Self-identified as someone with mixed ancestry.

Table 1: Patient characteristics by treatment allocation in the TOGETHER
trial

follow-up of all patients up to Sept 9, 2021. The trial is
registered at ClinicalTrials.gov (NCT04727424).

Role of the funding source
The funders of the study had no role in the study design,
data collection, data analysis, data interpretation, writing
of the report, or decision to submit for publication. The
executive committee take responsibility for the integrity of
the data and the accuracy of the data analysis. The trial
executive committee oversaw all aspects of trial conduct,
completeness, data accuracy and adherence of trial
conduct to the protocol and the committee vouch for the
accuracy and completeness of the data and for fidelity to
the protocol.

For the Open Science
Framework see https://www.
doi.org/10.17605/OSF.IO/EG37X
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Results
We have screened 9803 potential participants for
inclusion in this trial to date. The TOGETHER trial
enrolled its first participant on June 2, 2020 and
enrolment into the fluvoxamine group began on
Jan 20, 2021. As the trial is ongoing, herein we provide
descriptive summaries of only those randomly assigned
to fluvoxamine and its concurrent control. By
Intention-to-treat analysis

Modified intention-to-treat analysis

N

N

Relative risk
(95% BCI)

Fluvoxamine

741

79 (11%)

Placebo

756

119 (16%)

n (%)

0·68 (0·52–0·88)

740

78 (11%)

1 (ref)

752

115 (15%)

Relative risk
(95% BCI)
0·69 (0·53–0·90)
1 (ref)

BCI=Bayesian credible interval.

Table 2: Proportion of primary outcome events and relative risk of hospitalisation defined as either
retention in a COVID-19 emergency setting or transfer to tertiary hospital due to COVID-19 for patients
allocated fluvoxamine versus placebo

A

40

Intention-to-treat analysis

5

Density

30

Group

Probability (superiority)

Fluvoxamine
Placebo

99·8%
0·2%
Group
Fluvoxamine
Placebo

20

10

0

Relative risk 95% BCI 0·68 (0·52–0·88)

4

Posterior density

n (%)

Aug 5, 2021, 1497 recruited participants were randomly
assigned to fluvoxamine (n=741) or placebo (n=756), and
1826 were randomly assigned to other treatment groups
(figure 1). Herein, we present data on all patients
completing 28 days of follow-up as of Sept 9, 2021. The
median age was 50 years (range 18–102) and 862 (58%)
were women (table 1). Most participants self-identified
as mixed race 1428 (95%), 12 (1%) as white, 10 (1%) as
black or African heritage, the rest self-identified as
unknown 47 (3%). With respect to covariates of age,
body-mass index, and comorbidities, the groups were
generally well balanced (table 1). The mean number
of days with symptoms before randomisation was
3·8 days (SD 1·87).
All patients accessed care via a COVID-19 emergency
setting. There were a total of 180 patients in the
fluvoxamine group and 251 patients in the placebo group
who had any interaction with a COVID-19 emergency
setting. The relative risk (RR) for ever visiting a COVID-19
emergency setting was 0·73 (95% CI 0·62–0·88).

3

2

1

0·075

0·100

0·125

0·150

0·175

0

0·200

0·50

Event rate

B

40

Probability (superiority)

Fluvoxamine
Placebo

99·7%
0·3%

1·25

Relative risk 95% BCI 0·69 (0·53–0·90)

4

Posterior density

Density

5

Group

20

10

0

1·00

Relative risk

Modified intention-to-treat analysis

30

0·75

3

2

1

0·075

0·100

0·125

0·150

Event rate

0·175

0·200

0

0·50

0·75

1·00

1·25

Relative risk

Figure 2: Probability of efficacy and Bayesian relative risk of hospitalisation defined as either retention in a COVID-19 emergency setting or transfer to tertiary
hospital due to COVID-19 for fluvoxamine versus placebo
BCI=Bayesian credible interval.
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In the fluvoxamine group 79 (11%) participants had a
primary outcome event compared with 119 (16%) in
the placebo group (table 2). Most events (87%) were
hospitalisations. On the basis of the Bayesian betabinomial model, there was evidence of a benefit of
fluvoxamine reducing the composite primary endpoint
of hospitalisation defined as either retention in a
COVID-19 emergency setting or transfer to tertiary
hospital due to COVID-19 (RR 0·68; 95% Bayesian
credible interval [BCI] 0·52–0·88) in the ITT population
(figure 2A) and RR 0·69; 95% BCI 0·53–0·90 in a
modified ITT population (figure 2B). The number
needed to treat was 20. Per-protocol analysis showed a
larger treatment effect (0·34, 95% BCI 0·21–0·54). The
probability that the event rate was lower in the
fluvoxamine group compared with placebo was 99·8%
for the ITT population and 99·7% for the mITT
population (figure 2A, B). When the DSMC met on
Aug 5, 2021, it recommended that the TOGETHER trial
stop randomly assigning patients to the fluvoxamine
group, as this comparison had met the prespecified
superiority criterion for the primary endpoint (pre
specified superiority threshold 97·6%).
Table 3 presents findings from secondary outcome
analyses. There were no significant differences between
fluvoxamine and placebo for viral clearance at day 7
(p=0·090) and hospitalisations due to COVID (p=0·10),
all-cause hospitalisations (p=0·09), time to hospitalisation
(p=0·11), number of days in hospital (p=0·06), mortality
(p=0·24), time to death (p=0·49), number of days on
mechanical ventilation (p=0·90), time to recovery
(p=0·79) or the PROMIS Global Physical (p=0·55) or
Mental Scale (p=0·32; appendix 2 p 8).
84 participants stopped fluvoxamine and 64 participants
stopped placebo owing to issues of tolerability. Perprotocol findings among patients who reported optimal
adherence (greater than 80% for possible days) indicated
a significant treatment effect (RR 0·34; 95% BCI
0·21–0·54 for the primary outcome and for mortality
(odds ratio 0·09; 95% CI 0·01–0·47). With respect to
adverse events, there were no significant differences in
number of treatment emergent adverse events among
patients in the fluvoxamine and placebo groups.
In the prespecified subgroup analysis, we found
no evidence of moderation of treatment effect for
fluvoxamine compared with placebo, for subgroups of
age, sex, days since symptom onset, smoking status, or
comorbidities (figure 3, appendix 2 p 9).

Discussion
This is, to the best of our knowledge, the first large,
randomised controlled trial to test the efficacy of
fluvoxamine for acute treatment of COVID-19. We
found a clinically important absolute risk reduction
of 5·0%, and 32% RR reduction, on the primary
outcome of hospitalisation defined as either retention
in a COVID-19 emergency setting or transfer to tertiary
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Fluvoxamine

Placebo

Estimated
treatment effect
(95% CI)

p value

Viral clearance (day 7)

40/207 (19%)

58/221 (26%)

0·67 (0·42–1·06)*

0·090

Hospitalised for COVID

75/741 (10%)

97/756 (13%)

0·77 (0·55–1·05)*

0·10

All-cause hospitalisation

76/741 (10%)

99/756 (13%)

0·76 (0·58–1·04)*

0·088

Time to hospitalisation, days

5 (3 –7)

5 (3–7·5)

0·79 (0·58–1·06)†

0·11

Period of hospitalisation, days

8 (5–13)

6 (3–10·75)

1·23 (0·99–1·53)‡

0·059

Emergency setting visit for at
least 6 h

7/741 (1%)

36/756 (5%)

0·19 (0·08–0·41)*

0·0001

Time to the emergency visit for
at least 6 h, days

4 (3–7)

5 (3–8·25)

0·20 (0·09–0·44)†

0·002

Death, intention to treat

17/741 (2%)

25/756 (3%)

0·69 (0·36–1·27)*

0·24

Time to death, days

17 (9–21)

14 (8–20)

0·80 (0·43–1·51)†

0·49

Mechanical ventilation

26

34

0·77 (0·45–1·30)

0·33

1·03 (0·64–1·67)‡

0·90

618/738 (82%)

0·62 (0·48–0·77)*

0·0003

12/618 (2%)

0·09 (0·01–0·47)

0·022

Time on mechanical ventilator,
days
Adherence

5·5 (3–12·75)
548/741 (74%)

Death, per protocol

1/548 (<1%)

6·5 (2·25–12)

Treatment emergent adverse event
Grade 1

20/741 (3%)

11/756 (1%)

1·88 (0·91–4·09)*

0·096

Grade 2

72/741 (10%)

81/756 (11%)

0·91 (0·64–1·25)*

0·52

Grade 3

38/741 (5%)

50/756 (7%)

0·76 (0·49–1·18)*

0·22

Grade 4

21/741 (3%)

20/756 (3%)

1·07 (0·58–2·01)*

0·82

Grade 5

18/741 (2%)

26/756 (3%)

0·70 (0·37–1·28)*

0·25

Data are n/N (%) or median (IQR) unless otherwise stated. *Unadjusted odds ratio. †Unadjusted hazard ratio.
‡Exponentiated unadjusted estimates from a log-transformed linear regression.

Table 3: Secondary outcomes of fluvoxamine versus placebo in the TOGETHER trial

hospital due to COVID-19, consequent on the adminis
tration of fluvoxamine for 10 days. This study is only
the second study to show an important treatment
benefit for a repurposed drug in the early treatment
population.13 Our findings represent the complete
analysis of the trial after the DSMC recommended
stopping the active fluvoxamine group and all 28-day
follow-up of randomly assigned patients. Given
fluvoxamine’s safety, tolerability, ease of use, low cost,
and widespread availability, these findings might
influence national and international guidelines on the
clinical management of COVID-19.
Our results are consistent with an earlier smaller trial
done in the USA (led by EJL and AMR).6 That study
used a higher dose of fluvoxamine (100 mg three times
a day for 15 days) and included a lower risk group for
the primary outcome but found no clinical deterioration
among 80 patients receiving fluvoxamine versus six
cases among 72 patients receiving placebo. A large
observational study from France involved a different
population, 7230 hospitalised COVID-19 patients, and
reported a reduction in use of intubation or death with
use of SSRIs.5
The underlying mechanism of fluvoxamine for
COVID-19 disease remains uncertain. Although hypoth
eses include several potential mechanisms,4 the main
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Placebo
(n events)

Treatment
(n events)

Hazard ratio
(95% CI)

pinteraction

≤50

379 (41)

368 (23)

0·57 (0·34–0·95)

0·60

>50

328 (72)

327 (50)

0·67 (0·47–0·96)

Female

453 (61)

409 (28)

0·49 (0·31–0·77)

Male

303 (58)

332 (51)

0·80 (0·55–1·16)

Age (years)

Sex
0·10

Body-mass index (kg/m2)
<30

373 (52)

355 (34)

0·67 (0·44–1·03)

≥30

375 (67)

376 (44)

0·64 (0·44–0·94)

0–3 days

310 (39)

328 (30)

0·72 (0·45–1·15)

4–7 days

267 (44)

239 (31)

0·77 (0·49–1·23)

0·87

Time from onset of symptoms
0·82

Cardiovascular disease
No

454 (60)

435 (39)

0·67 (0·45–1·00)

Yes

302 (59)

304 (40)

0·65 (0·44–0·97)

No

747 (117)

733 (79)

0·67 (0·51–0·90)

0·53

Yes

8 (2)

4 (0)

No

702 (115)

704 (78)

0·66 (0·50–0·88)

0·60

Yes

54 (4)

35 (1)

0·37 (0·04–3·35)

0·94

Use of corticoid therapy

Chronic kidney disease

Smoking status
Current

64 (5)

47 (3)

0·80 (0·19–3·33)

Former

89 (17)

107 (10)

0·46 (0·21–1·00)

Never

601 (97)

586 (66)

0·69 (0·50–0·94)
0·35

0·50

0·75

1·0

0·60

1·5

Favours fluvoxamine Favours placebo

Figure 3: Subgroup analyses of fluvoxamine versus placebo in the TOGETHER Trial

reason for the initial study of fluvoxamine as a treatment of
COVID-19 was its anti-inflammatory action through
activation of the S1R.14 S1R is an endoplasmic reticulum
(ER) chaperone membrane protein involved in many
cellular functions,15 including regulation of ER stress
response–unfolded protein response and regulation of
cytokine production in response to inflammatory triggers.16
In the presence of fluvoxamine, S1R might prevent the ER
stress sensor inositol-requiring enzyme 1α from splicing
and activating the mRNA of X-box protein 1, a key regulator
of cytokine production including interleukins IL-6, IL-8,
IL-1β, and IL-12. In a 2019 study by Rosen and colleagues,
fluvoxamine showed benefit in preclinical models of
inflammation and sepsis through this mechanism.16
A second mechanism might be fluvoxamine’s
antiplatelet activity.17 SSRIs can prevent loading of
serotonin into platelets and inhibit platelet activation,
which might reduce the risk of thrombosis, and these
antiplatelet effects can be cardioprotective. Finally,
another potential mechanism of action might be related
to the effect of fluvoxamine in increasing plasma levels of
melatonin.16 In vitro and animal studies are needed to
help clarify the most probable mechanism(s). Biomarker
studies included as part of future randomised controlled
trials might also help to clarify mechanisms.
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Since the start of the COVID-19 pandemic, there have
been more than 2800 randomised controlled trials
registered on ClinicalTrials.gov. However, fewer than 300
have been reported and most clinical trials have been
small and underpowered, with sample sizes less than
100. In many cases, these trials have been unsuccessful
at recruiting as the local epidemics occur in waves
and sustainable infrastructure to maintain staff or local
interest for recruitment is lacking. The trials that provide
the clearest medical understanding tend to be the larger
platform trials, such as SOLIDARITY,17 RECOVERY,18
PRINCIPLE,11 and REMAP-CAP.19 As a result, we actively
collaborate with other investigators running trials with
overlapping interventions so that they can be aware of
our study decisions and establish whether they should
influence their respective trials.
Strengths of our trial include the rapid recruitment and
enrolment of high-risk patients for the development of
severe COVID-19. Our recruitment strategy involves
engage
ment with the local public health system, thus
allowing recruitment that frequently exceeds 20 patients
per day. We enrolled only participants with diagnosed
COVID-19 and less than 7 days of symptom onset using a
com
mercially available COVID-19 rapid antigen test
(Panbio, Abbott Rapid Diagnostics Jena, Jena, Germany).
www.thelancet.com/lancetgh Vol 10 January 2022
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The concordance of COVID-19 positive tests with RT-PCR
was evaluated on the group of participants with PCR
evaluations and a concordance rate of greater than 99% on
both tests collected at baseline was found. In this trial we
did not enrol participants without positive COVID-19
tests, nor those who were asymptomatic SARS-CoV-2
positive. Our primary outcome is hospitalisation defined
as either retention in a COVID-19 emergency setting for
more than 6 h or transfer to tertiary hospital due to
COVID-19. The event adjudication committee did count
patient wait times as contributing to a primary endpoint.
Specialised emergency settings were developed to respond
to the Brazilian epidemic and we considered prolonged
observation and treatment in these settings as equivalent
in importance to hospitalisation as many patients who
typically would be hospitalised were prevented from doing
so owing to hospital over-capacity. In our trial, 87% of all
primary outcome events eventually resulted in transfer to
a tertiary hospital. Patients observed in both the emergency
setting and hospital were counted only once. Our subgroup analyses examined pre-determined population
groups and tests for interaction did not detect differing
effects for any sub-group. Female sex was identified as a
signficant sub-group favouring fluvoxamine while male
sex was not, however we did not detect differing effects
between the groups.
Our understanding of the epidemiology of COVID-19 as
well as its disease progression and outcomes have evolved
since beginning this platform trial in June, 2020. Early
studies assessed the effects of interventions on viral load
and clearance, whereas later studies also evaluate more
clinical outcomes. We made adjustments to the trial
according to prespecified rules and in com
munication
with the appropriate ethics review committees that allowed
us to respond to the epidemic waves while maintaining
high rates of recruitment. Unlike many outpatient clinical
trials, our study involves direct patient contact through the
use of medical students, nurses, and physicians who do
at-home visits as well as follow-up via telecommunications.
Given the rapid recruitment of patients in combination
with the high event rate of COVID-19 emergency setting
visits and hospitalisations, we were able to evaluate the
effects of interventions when portions of the planned
population had been recruited. The period between first
recruitment of a patient on fluvoxamine and the final data
cut for our trial was 219 days.
Major limitations of our trial are related to the
challenges of doing a trial in a disease that is not well
characterised. There is no standard of care that exists for
early treatment of COVID-19 and various advocacy groups
promote different interventions, including some of those
evaluated in this and our previous trials.20 Furthermore,
there is little understanding of who is at greatest risk of
disease progression from this disease as some patients
with numerous risk factors do recover quickly whereas
some others with less established risk factors might not.
Our population had a higher rate of hospitalisation events
www.thelancet.com/lancetgh Vol 10 January 2022

than observed in most clinical trials,20 thus permitting
inferences on treatment effects in this higher-risk
population. Although intention-to-treat analysis provides
more real-world evidence than per-protocol analysis, we
found that patients who reported optimal adherence
(greater than 80% for possible days—our per-protocol
analysis) had a greater treatment benefit, suggesting
that intensifying adherence to treatment might have
considerable clinical benefits. However, adherence
might be related to tolerability. 84 participants stopped
fluvoxamine and 64 participants stopped in the placebo
group for this reason. Finally, when the trial began,
vaccines were not available in Brazil but became more
widely available as the trial progressed. Although we
modified inclusion criteria and permitted vaccinated
patients during the trial, we believe this had minimal
effect on the primary outcome as only 86 (6%) of
1497 reported at least one dose of a COVID-19 vaccine at
the end of the trial.
Our trial has found that fluvoxamine, an inexpensive
existing drug, reduces the need for advanced disease
care in this high-risk population. A 10-day course of
fluvoxamine costs approximately US$4 even in wellresourced settings.21 Our study compares favourably with
the treatment effects of more expensive treatments
including monoclonal antibodies for outpatient treat
ment.20,22,23 The absolute number of serious adverse
events associated with fluvoxamine was lower than for
placebo and this might reflect the modulatory effect
of fluvoxamine on systemic inflammation in these
participants. Lower respiratory tract infections were
reported less frequently in patients in the fluvoxamine
group than those in the placebo group. This is concordant
with the reduction of hospital admissions in patients
with confirmed COVID-19 treated with fluvoxamine, and
the numerically lower number of patients requiring
mechanical ventilation.
Fluvoxamine is widely available but is not on the WHO
Essential Medicines List,24 whereas a closely related SSRI,
fluoxetine, is on the list. It is now crucial to establish
whether a class effect exists and whehese drugs can be
used interchangeably for COVID-19. The important
findings that inhaled budesonide decreased time to
recovery11 among a similar population to our trial and had
a trend towards decreased hospitalisations suggests that
this as an alternative or additional intervention for
outpatient care that should be evaluated. The PRINCIPLE
trial evaluated time to recovery by means of self-reported
recovery up to 28 days after randomisation to budesonide.11
Our trial differed as we evaluated improvement in the
WHO categorisation of disease disability up to days 14 and
then 28 (appendix 2 p 7). Finally, our study was among
primarily unvaccinated patients. Further evidence of
treatment benefits are needed to establish the effect of
fluvoxamine among vaccinated populations.
Use of interventions, including fluvoxamine, to prevent
progression of illness and hospitalisation is critically
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dependent on identifying higher-risk individuals.
Unselected populations will have a lower risk. What
absolute reduction in risk of clinical deterioration would
motivate patients to choose treatment (probably the
approximately 5% that we observed, but perhaps not
much lower) remains uncertain. These considerations
raise the importance of the development of a validated
prediction rule for deterioration in patients in the early
stages of COVID-19 infection.
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